Ego opens flammable goods manufacturing facility


Australian manufacturing is getting a boost this week as Ego Pharmaceuticals opens its new $15 million dollar flammable goods manufacturing facility.

Ego’s managing director Alan Oppenheim says the new facility enables the family owned company to double its bottle filling capacity and grow its booming export business.

“The new $15 million dollar facility increases our total production capabilities across our site dramatically. It’s an investment in new technology, new processes, jobs in Australia, economic uplift and skin health for the community,” Oppenheim says.

The state of the art facility to will produce alcohol-based hand sanitiser at large scale to help prevent the spread of disease, amongst other skincare products.

Oppenheim says the move would help the people of Australia in the event of a future health pandemic as hand hygiene is recognised as the most important way of preventing the spread of germs, bacteria and viruses.

“It is a good strategy for Australia to have secured its own huge new manufacturing facility of quality hand sanitiser to help protect against the spread of viruses,” he says.

The move also opens up an increase the ability to fulfil big demands coming from Asia and the Middle East.

In 2014 when the MERS epidemic hit, an international Ministry of Health tendered an order for 10 million anti bacterial hand sanitisers with specific interest in the quality of Aqium. However at the time Ego’s facility to produce Aqium couldn’t cope with the quantity and short turnaround demand and so the opportunity was lost.

Australian Industry Group CEO Innes Willox says the project signals the good health of pharmaceutical manufacturing in Australia amongst gloom and doom stories.

“Ego’s expansion is still further evidence that manufacturing in Australia can prosper where there is a strong commitment to innovation and a willingness to invest in opportunity. There is a bright future for agile manufacturers that can remake themselves to meet new markets,” Willox says.

Oppenheim says remaining in Australia is a core strategy to Ego’s business success.

“We are very passionate about remaining an Australian company, we manufacture in Australia, we do our research and development here – we read about companies constantly investing more and more of its manufacturing internationally and yet we have so much talent and opportunities in Australia – it just takes smart planning and strong investment for the long term,” he says.

 

 

Previous Poll: How are you handling the newly listed Hep C drugs?
Next HMR barriers hamper deprescribing

NOTICE: It can sometimes take awhile for comment submissions to go through, please be patient.